Skip to main content

3.

3

Kaplan-Meier estimates of progression-free survival (PFS) (in months) for patients with triple-negative breast cancer (TNBC), regardless of lines of therapy, using combined baseline circulating tumor cell-natural killer cell (CTC-NK) levels. (A) Comparison of area under the curve (AUC) among CTC, NK and CTC-NK using receiver operating characteristic (ROC) curve analyses; (B) Kaplan-Meier survival analysis for patients with CTC>2.0 & NK>8.0% and CTC≤2.0 & NK>8.0% (P=0.049).